Effect of Low-Dose Esketamine Combined with Propofol on Postoperative Fatigue in Colonoscopy: A Randomized Clinical Trial.

IF 2.8 3区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics
Therapeutics and Clinical Risk Management Pub Date : 2025-05-29 eCollection Date: 2025-01-01 DOI:10.2147/TCRM.S521961
Xuemei Sun, Qiuling Du, Yongjie Liang, Lili Tang, Qingfeng Wei, Peipei Guo, Xuesheng Liu
{"title":"Effect of Low-Dose Esketamine Combined with Propofol on Postoperative Fatigue in Colonoscopy: A Randomized Clinical Trial.","authors":"Xuemei Sun, Qiuling Du, Yongjie Liang, Lili Tang, Qingfeng Wei, Peipei Guo, Xuesheng Liu","doi":"10.2147/TCRM.S521961","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Postoperative fatigue (POF) is a common occurrence following colonoscopy, primarily attributed to bowel preparation and endoscopic probe stimulation, and is associated with worse postoperative outcomes. Esketamine, an antidepressant anesthetic, has shown the potential to enhance postoperative recovery through various mechanisms. We hypothesized that the low-dose esketamine could alleviate POF in outpatients undergoing colonoscopy.</p><p><strong>Methods: </strong>200 participants scheduled for painless colonoscopy were enrolled, with 151 patients included in the primary endpoint analysis. Patients were randomly received 0.15 mg/kg esketamine or 0.1 μg/kg sufentanil before anesthesia induction. The primary outcome was the incidence of POF, assessed using the Identity-Consequence Fatigue Scale-10 (ICFS-10) scores at 30 min after colonoscopy. Secondary outcomes included ICFS-10 scores at baseline and 1 day post-colonoscopy, time to discharge and patients' satisfaction.</p><p><strong>Results: </strong>The incidence of POF was significantly lower in the esketamine group (Group E) compared to the sufentanil group (Group S) (28% vs 44%, <i>P</i> = 0.036). There were no significant differences in ICFS-10 scores between the two groups at baseline and 1 day post-colonoscopy. However, discharge time was significantly shorter in Group E than in Group S (25 min vs 30 min, <i>P</i> = 0.001). In Group E, there was improved hemodynamic stability and greater patients' satisfaction.</p><p><strong>Conclusion: </strong>The administration of esketamine significantly reduced the incidence of POF and shortened discharge time in patients undergoing colonoscopy. A regimen of 0.15 mg/kg esketamine combined with propofol proved to be an effective anesthesia strategy for painless colonoscopy.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"807-816"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129815/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S521961","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Postoperative fatigue (POF) is a common occurrence following colonoscopy, primarily attributed to bowel preparation and endoscopic probe stimulation, and is associated with worse postoperative outcomes. Esketamine, an antidepressant anesthetic, has shown the potential to enhance postoperative recovery through various mechanisms. We hypothesized that the low-dose esketamine could alleviate POF in outpatients undergoing colonoscopy.

Methods: 200 participants scheduled for painless colonoscopy were enrolled, with 151 patients included in the primary endpoint analysis. Patients were randomly received 0.15 mg/kg esketamine or 0.1 μg/kg sufentanil before anesthesia induction. The primary outcome was the incidence of POF, assessed using the Identity-Consequence Fatigue Scale-10 (ICFS-10) scores at 30 min after colonoscopy. Secondary outcomes included ICFS-10 scores at baseline and 1 day post-colonoscopy, time to discharge and patients' satisfaction.

Results: The incidence of POF was significantly lower in the esketamine group (Group E) compared to the sufentanil group (Group S) (28% vs 44%, P = 0.036). There were no significant differences in ICFS-10 scores between the two groups at baseline and 1 day post-colonoscopy. However, discharge time was significantly shorter in Group E than in Group S (25 min vs 30 min, P = 0.001). In Group E, there was improved hemodynamic stability and greater patients' satisfaction.

Conclusion: The administration of esketamine significantly reduced the incidence of POF and shortened discharge time in patients undergoing colonoscopy. A regimen of 0.15 mg/kg esketamine combined with propofol proved to be an effective anesthesia strategy for painless colonoscopy.

Abstract Image

Abstract Image

Abstract Image

小剂量艾氯胺酮联合异丙酚对结肠镜术后疲劳的影响:一项随机临床试验。
目的:术后疲劳(POF)是结肠镜检查后常见的现象,主要归因于肠道准备和内镜探头刺激,并与较差的术后结果相关。艾氯胺酮,一种抗抑郁麻醉剂,已经显示出通过各种机制增强术后恢复的潜力。我们假设低剂量艾氯胺酮可以减轻门诊结肠镜检查患者的POF。方法:纳入200名计划进行无痛结肠镜检查的参与者,其中151名患者纳入主要终点分析。患者在麻醉诱导前随机给予0.15 mg/kg艾氯胺酮或0.1 μg/kg舒芬太尼。主要终点是POF的发生率,在结肠镜检查后30分钟使用身份-后果疲劳量表-10 (ICFS-10)评分进行评估。次要结局包括基线和结肠镜检查后1天的ICFS-10评分、出院时间和患者满意度。结果:艾氯胺酮组(E组)POF发生率明显低于舒芬太尼组(S组)(28% vs 44%, P = 0.036)。两组在基线和结肠镜检查后1天的ICFS-10评分无显著差异。E组患者出院时间明显短于S组(25 min vs 30 min, P = 0.001)。E组血流动力学稳定性改善,患者满意度提高。结论:应用艾氯胺酮可显著降低结肠镜患者POF的发生率,缩短出院时间。0.15 mg/kg艾氯胺酮联合异丙酚被证明是无痛结肠镜检查的有效麻醉策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutics and Clinical Risk Management
Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-
CiteScore
5.30
自引率
3.60%
发文量
139
审稿时长
16 weeks
期刊介绍: Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信